PRecision Ecmo in CardIogenic Shock Evaluation

Launched by AUSTRALIAN AND NEW ZEALAND INTENSIVE CARE RESEARCH CENTRE · Feb 19, 2023

Keywords

ClinConnect Summary

The PRECISE Study is a research project aimed at improving the care of patients experiencing a serious condition called cardiogenic shock, where the heart is unable to pump enough blood to meet the body’s needs. This study will explore whether certain blood tests, known as biomarkers, can help doctors decide who will benefit the most from a life-support treatment called venoarterial (VA) ECMO. While ECMO can save lives, it can also be costly and may not help everyone, so understanding who will gain the most from it is important.

To participate in the study, patients must be at least 18 years old and be starting VA ECMO as part of their treatment. Participants will provide a small blood sample at different times during their ECMO treatment, which will help researchers track important outcomes, like the level of disability six months later. This study aims to provide better care for patients who are very sick and to make the use of this complex treatment more effective.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients who will be commencing on VA ECMO (for cardiogenic shock or ECPR)
• • 18 years old or older
• • Patients who will be enrolled in the EXCEL Registry (HREC Project 534/18)
• Exclusion Criteria:
• • Patients who are already on ECMO, or where
• • There are inadequate resources to complete the study